Frederick Howard, MD, explored the evolving intersection of artificial intelligence (AI), computational pathology, and precision breast oncology.
|Articles|July 23, 2009
Oncology NEWS International
- Oncology NEWS International Vol 18 No 7
- Volume 18
- Issue 7
M.D. Anderson group unveils new p53 marker
Houston-based investigators have identified a protein that marks the tumor suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells.
Advertisement
Houston-based investigators have identified a protein that marks the tumor suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells.
Trim24 feeds p53 to the proteasome by attaching targeting ubiquitins to the tumor suppressor. It is highly expressed in tumors and is a target of two known oncogenes in some forms of leukemia (PNAS online, June 30, 2009)
Articles in this issue
about 17 years ago
Less is more when it comes to serial CA125 testing in ovarian cancerabout 17 years ago
Treatment varies widely in chronic myeloid leukemiaabout 17 years ago
Oncology takes blame for rising healthcare costabout 17 years ago
Healthcare advocates call for universal coverage, acknowledge challengesabout 17 years ago
NSABP chair admits ‘failure’ in C-08 trial, denies defeatAdvertisement
Related to this article
“Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon).
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical Oncology Congress 2026.
The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.
Long-term QUILT-3.032 data showed a 71% CR rate, with a median duration of 26.6 months with nogapendekin alfa inbakicept/BCG in BCG-unresponsive NMIBC.
The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk non–muscle invasive bladder cancer.
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer
2
Ris-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC
3
FDA Accepts NDA for UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC
4
Sequencing CAR T-Cell Therapy and Bispecifics to Preserve T-Cell Fitness
5